A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia

This study is testing a new treatment approach for a specific subtype of acute myeloid leukemia (AML) — a blood cancer — that carries a KIT gene mutation along with certain chromosomal changes known as core binding factor AML. **You may be eligible if:** - You are 18 or older - You have been newly diagnosed with AML carrying the KIT mutation and one of two specific chromosomal changes (t(8;21) or inv(16)) - You have not previously received chemotherapy (small amounts of specific drugs are acceptable) - Your heart, liver, and kidney function are within acceptable ranges **You may NOT be eligible if:** - You have a different subtype of AML (such as acute promyelocytic leukemia) - You have a serious active infection - You are pregnant or breastfeeding - You have significant heart disease - You have received prior stem cell transplantation for this condition Talk to your doctor to see if this trial is right for you.